Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Medtronic
Harvard Business School

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR PEGAPTANIB SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Pegaptanib Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00040313 ↗ Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula Completed Eyetech Pharmaceuticals Phase 2 2002-10-01 The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled
NCT00087763 ↗ Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) Completed Pfizer Phase 2 2004-03-01 The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
NCT00087763 ↗ Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) Completed Eyetech Pharmaceuticals Phase 2 2004-03-01 The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
NCT00088192 ↗ Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) Completed Pfizer N/A 2004-07-01 To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pegaptanib Sodium

Condition Name

Condition Name for Pegaptanib Sodium
Intervention Trials
Macular Degeneration 8
Diabetic Macular Edema 5
Age-Related Macular Degeneration 5
Neovascular Age-related Macular Degeneration 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pegaptanib Sodium
Intervention Trials
Macular Degeneration 17
Macular Edema 11
Edema 7
Retinal Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pegaptanib Sodium

Trials by Country

Trials by Country for Pegaptanib Sodium
Location Trials
United States 91
Japan 38
France 6
Spain 4
Canada 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pegaptanib Sodium
Location Trials
Texas 9
California 7
Florida 6
Michigan 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pegaptanib Sodium

Clinical Trial Phase

Clinical Trial Phase for Pegaptanib Sodium
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2/Phase 3 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pegaptanib Sodium
Clinical Trial Phase Trials
Completed 22
Terminated 6
Withdrawn 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pegaptanib Sodium

Sponsor Name

Sponsor Name for Pegaptanib Sodium
Sponsor Trials
Pfizer 20
Eyetech Pharmaceuticals 11
Postgraduate Institute of Medical Education and Research 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pegaptanib Sodium
Sponsor Trials
Industry 34
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
McKinsey
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.